EXENATIDE TREATMENT REDUCES THYROID GLAND VOLUME, BUT HAS NO EFFECT ON THE SIZE OF THYROID NODULES

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Exenatide, a Glucagon-like Peptide-1 receptor agonist, is a common treatment for type 2 diabetes mellitus (T2DM).
• Previous research on exenatide's effects on the thyroid gland has yielded limited and contradictory findings.
• Understanding these effects is crucial for comprehensive patient management.

Purpose of the Study:

• To investigate the impact of exenatide on both the structural and functional aspects of the thyroid gland in T2DM patients.
• To assess changes in thyroid volume, hormone levels, and nodule characteristics following exenatide therapy.

Main Methods:

• A prospective study involving 39 obese T2DM patients over a 6-month period.
• Exenatide treatment initiated at 5μg twice daily, escalated to 10μg twice daily after 4 weeks.
• Comparison of thyroid ultrasonography, thyroid function tests, serum carcinoembryonic antigen (CEA), and calcitonin levels before and after treatment.

Main Results:

• A statistically significant reduction in total thyroid volume (p=0.043) was observed.
• Serum thyroid stimulating hormone (TSH) levels also significantly decreased (p=0.007).
• No significant changes were noted in anti-thyroid peroxidase (ATPO), anti-thyroglobulin (ATGl), free thyroxine (fT4), free triiodothyronine (fT3), CEA, or calcitonin levels. Thyroid nodule size and appearance remained unchanged.

Conclusions:

• Six months of exenatide treatment effectively reduced thyroid volume and serum TSH levels in T2DM patients.
• Exenatide did not demonstrate any significant effect on the development or characteristics of thyroid nodules.
• The treatment did not alter serum CEA or calcitonin levels, suggesting no impact on medullary thyroid carcinoma risk markers.